Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Verrica Pharmaceuticals ( (VRCA) ) is now available.
On June 10, 2025, Verrica Pharmaceuticals Inc. entered into a sixth amendment and waiver to its Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP and other lenders. The amendment includes a waiver of certain covenants related to financial statement qualifications for the quarters ending June 30, 2025, and September 30, 2025, as well as the year ending December 31, 2025. This move allows Verrica Pharmaceuticals to avoid a ‘going concern’ qualification, potentially stabilizing its financial outlook and reassuring stakeholders about its operational continuity.
The most recent analyst rating on (VRCA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
The overall score reflects significant financial challenges and a negative valuation, offset partially by positive technical indicators and supportive corporate events. The company’s financial instability is the most critical factor, demanding strategic action for improvement.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Average Trading Volume: 375,880
Technical Sentiment Signal: Sell
Current Market Cap: $55.59M
Find detailed analytics on VRCA stock on TipRanks’ Stock Analysis page.